Literature DB >> 22343308

Ruminococcus bromii is a keystone species for the degradation of resistant starch in the human colon.

Xiaolei Ze1, Sylvia H Duncan, Petra Louis, Harry J Flint.   

Abstract

The release of energy from particulate substrates such as dietary fiber and resistant starch (RS) in the human colon may depend on the presence of specialist primary degraders (or 'keystone species') within the microbial community. We have explored the roles of four dominant amylolytic bacteria found in the human colon in the degradation and utilization of resistant starches. Eubacterium rectale and Bacteroides thetaiotaomicron showed limited ability to utilize RS2- and RS3-resistant starches by comparison with Bifidobacterium adolescentis and Ruminococcus bromii. In co-culture, however, R. bromii proved unique in stimulating RS2 and RS3 utilization by the other three bacterial species, even in a medium that does not permit growth of R. bromii itself. Having previously demonstrated low RS3 fermentation in vivo in two individuals with undetectable populations of R. bromii-related bacteria, we show here that supplementation of mixed fecal bacteria from one of these volunteers with R. bromii, but not with the other three species, greatly enhanced the extent of RS3 fermentation in vitro. This argues strongly that R. bromii has a pivotal role in fermentation of RS3 in the human large intestine, and that variation in the occurrence of this species and its close relatives may be a primary cause of variable energy recovery from this important component of the diet. This work also indicates that R. bromii possesses an exceptional ability to colonize and degrade starch particles when compared with previously studied amylolytic bacteria from the human colon.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22343308      PMCID: PMC3400402          DOI: 10.1038/ismej.2012.4

Source DB:  PubMed          Journal:  ISME J        ISSN: 1751-7362            Impact factor:   10.302


  35 in total

1.  Dominant and diet-responsive groups of bacteria within the human colonic microbiota.

Authors:  Alan W Walker; Jennifer Ince; Sylvia H Duncan; Lucy M Webster; Grietje Holtrop; Xiaolei Ze; David Brown; Mark D Stares; Paul Scott; Aurore Bergerat; Petra Louis; Freda McIntosh; Alexandra M Johnstone; Gerald E Lobley; Julian Parkhill; Harry J Flint
Journal:  ISME J       Date:  2010-08-05       Impact factor: 10.302

2.  Screening for and identification of starch-, amylopectin-, and pullulan-degrading activities in bifidobacterial strains.

Authors:  Sinéad M Ryan; Gerald F Fitzgerald; Douwe van Sinderen
Journal:  Appl Environ Microbiol       Date:  2006-08       Impact factor: 4.792

Review 3.  Dietary fibre and colorectal cancer: a model for environment--gene interactions.

Authors:  Graeme P Young; Ying Hu; Richard K Le Leu; Laura Nyskohus
Journal:  Mol Nutr Food Res       Date:  2005-06       Impact factor: 5.914

4.  Comparative effects of three resistant starch preparations on transit time and short-chain fatty acid production in rats.

Authors:  L R Ferguson; C Tasman-Jones; H Englyst; P J Harris
Journal:  Nutr Cancer       Date:  2000       Impact factor: 2.900

5.  Hydrothermal treatment of Novelose 330 results in high yield of resistant starch type 3 with beneficial prebiotic properties and decreased secondary bile acid formation in rats.

Authors:  Gisela Jacobasch; Gerhard Dongowski; Detlef Schmiedl; Katrin Müller-Schmehl
Journal:  Br J Nutr       Date:  2006-06       Impact factor: 3.718

6.  Selective colonization of insoluble substrates by human faecal bacteria.

Authors:  E Carol McWilliam Leitch; Alan W Walker; Sylvia H Duncan; Grietje Holtrop; Harry J Flint
Journal:  Environ Microbiol       Date:  2007-03       Impact factor: 5.491

7.  Towards the human intestinal microbiota phylogenetic core.

Authors:  Julien Tap; Stanislas Mondot; Florence Levenez; Eric Pelletier; Christophe Caron; Jean-Pierre Furet; Edgardo Ugarte; Rafael Muñoz-Tamayo; Denis L E Paslier; Renaud Nalin; Joel Dore; Marion Leclerc
Journal:  Environ Microbiol       Date:  2009-07-06       Impact factor: 5.491

8.  Influence of mucin on glycosidase, protease and arylamidase activities of human gut bacteria grown in a 3-stage continuous culture system.

Authors:  G T Macfarlane; S Hay; G R Gibson
Journal:  J Appl Bacteriol       Date:  1989-05

9.  Phylotypes related to Ruminococcus bromii are abundant in the large bowel of humans and increase in response to a diet high in resistant starch.

Authors:  Guy C J Abell; Caroline M Cooke; Corinna N Bennett; Michael A Conlon; Alexandra L McOrist
Journal:  FEMS Microbiol Ecol       Date:  2008-06-24       Impact factor: 4.194

10.  The species composition of the human intestinal microbiota differs between particle-associated and liquid phase communities.

Authors:  Alan W Walker; Sylvia H Duncan; Hermie J M Harmsen; Grietje Holtrop; Gjalt W Welling; Harry J Flint
Journal:  Environ Microbiol       Date:  2008-08-15       Impact factor: 5.491

View more
  269 in total

1.  Insights in the ecology and evolutionary history of the Miscellaneous Crenarchaeotic Group lineage.

Authors:  Mireia Fillol; Jean-Christophe Auguet; Emilio O Casamayor; Carles M Borrego
Journal:  ISME J       Date:  2015-08-18       Impact factor: 10.302

Review 2.  Evolutionary and ecological forces that shape the bacterial communities of the human gut.

Authors:  J S Messer; E R Liechty; O A Vogel; E B Chang
Journal:  Mucosal Immunol       Date:  2017-02-01       Impact factor: 7.313

Review 3.  The abundance and variety of carbohydrate-active enzymes in the human gut microbiota.

Authors:  Abdessamad El Kaoutari; Fabrice Armougom; Jeffrey I Gordon; Didier Raoult; Bernard Henrissat
Journal:  Nat Rev Microbiol       Date:  2013-06-10       Impact factor: 60.633

4.  Effects of Atypical Antipsychotic Treatment and Resistant Starch Supplementation on Gut Microbiome Composition in a Cohort of Patients with Bipolar Disorder or Schizophrenia.

Authors:  Stephanie A Flowers; Nielson T Baxter; Kristen M Ward; A Zarina Kraal; Melvin G McInnis; Thomas M Schmidt; Vicki L Ellingrod
Journal:  Pharmacotherapy       Date:  2019-02-03       Impact factor: 4.705

5.  Pharmacological Activation of PXR and CAR Downregulates Distinct Bile Acid-Metabolizing Intestinal Bacteria and Alters Bile Acid Homeostasis.

Authors:  Joseph L Dempsey; Dongfang Wang; Gunseli Siginir; Qiang Fei; Daniel Raftery; Haiwei Gu; Julia Yue Cui
Journal:  Toxicol Sci       Date:  2019-03-01       Impact factor: 4.849

6.  Complete genome sequence of Bifidobacterium adolescentis P2P3, a human gut bacterium possessing strong resistant starch-degrading activity.

Authors:  Dong-Hyun Jung; Won-Hyong Chung; Dong-Ho Seo; Ye-Jin Kim; Young-Do Nam; Cheon-Seok Park
Journal:  3 Biotech       Date:  2020-01-07       Impact factor: 2.406

7.  Genomic characterization and transcriptional studies of the starch-utilizing strain Bifidobacterium adolescentis 22L.

Authors:  Sabrina Duranti; Francesca Turroni; Gabriele Andrea Lugli; Christian Milani; Alice Viappiani; Marta Mangifesta; Laura Gioiosa; Paola Palanza; Douwe van Sinderen; Marco Ventura
Journal:  Appl Environ Microbiol       Date:  2014-07-25       Impact factor: 4.792

8.  Impact of diet and individual variation on intestinal microbiota composition and fermentation products in obese men.

Authors:  Anne Salonen; Leo Lahti; Jarkko Salojärvi; Grietje Holtrop; Katri Korpela; Sylvia H Duncan; Priya Date; Freda Farquharson; Alexandra M Johnstone; Gerald E Lobley; Petra Louis; Harry J Flint; Willem M de Vos
Journal:  ISME J       Date:  2014-04-24       Impact factor: 10.302

9.  Gut microbiota dysbiosis is associated with malnutrition and reduced plasma amino acid levels: Lessons from genome-scale metabolic modeling.

Authors:  Manish Kumar; Boyang Ji; Parizad Babaei; Promi Das; Dimitra Lappa; Girija Ramakrishnan; Todd E Fox; Rashidul Haque; William A Petri; Fredrik Bäckhed; Jens Nielsen
Journal:  Metab Eng       Date:  2018-07-31       Impact factor: 9.783

Review 10.  Prebiotics in vitro digestion by gut microbes, products' chemistry, and clinical relevance.

Authors:  Tolulope Joshua Ashaolu; Joseph O Ashaolu
Journal:  Appl Microbiol Biotechnol       Date:  2020-11-17       Impact factor: 4.813

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.